Colin Watts, chief innovation officer at Walgreen Co., has left the drug chain to join Weight Watchers International Inc.


Colin Watts, Weight Watchers, Walgreens, senior vice president of wellness, global innovation, weight management, David Burwick, chief innovation officer, health care, drug chain, Ken Finnegan




























































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Retail News Breaks Archives

Walgreens' Watts moves to Weight Watchers

December 12th, 2011

NEW YORK – Colin Watts, chief innovation officer at Walgreen Co., has left the drug chain to join Weight Watchers International Inc.

Colin Watts

The weight management service provider said Monday that Watts has been appointed senior vice president of wellness and global innovation and will start at the company on Jan. 3.

Watts will oversee Weight Watchers' North American business-to-business and health care operations, along with its global innovation and consumer insights teams. He will report to David Burwick, president for North America.

Most recently, Watts was corporate vice president and chief innovation officer at Walgreens, where he led the recently created corporate innovation division. He joined Walgreens in 2008 and was named as a corporate vice president in January 2010.

Taking over Watts' duties at Walgreens will be Ken Finnegan, divisional vice president of health care new business development, according to a Walgreens spokesman.

Weight Watchers noted that Watts brings a wide range of experience in general management, marketing and innovation from consumer products and health care companies.

Before joining Walgreens, Watts served in key senior leadership roles at Johnson & Johnson as president of McNeil Nutritionals Worldwide and McNeil Consumer Healthcare Worldwide, in which he was responsible for building businesses such as Tylenol, Motrin, Imodium and Splenda.He  also held various marketing roles early in his career at Johnson & Johnson and Nabisco.

"Colin comes to us at a very exciting time in North America as we accelerate the growth of our B2B/Healthcare business, starting with large, self-insured companies and leading to new partnerships with payers, providers and physicians that will significantly expand the reach and affordability of our services," Burwick said in a statement. "Colin's broad array of experiences and knowledge of the health care space and innovation development and commercialization make him uniquely qualified to transform our efforts in these critical areas."

*Editor's Note: Article updated with information from Walgreens.

Advertisement